header image IMMUNOSCORE leftbar
  History  
  Partners  
  Projects  
  Research  
  Papers  
  Core facility  
  Links  
  HalioDx  
ici
INDUSTRIALS

HalioDx
Immuno-Oncology Diagnostic company, Co-founder Dr. Jérôme Galon

HalioDx vision is to create a leader in Immuno-Oncology diagnostics, the emerging segment of the cancer molecular diagnostic market (MDx).

HalioDx plan is to develop a unique portfolio of MDx -IVDs solutions dedicated to Immuno-Oncology.

Dr. Jérôme Galon is a co-founder of HalioDx. The co-founders are experienced executives with extensive track records in the Diagnostic Industry, Pharma & BioTech Management.

The company is a spin-off of Qiagen Marseille, a subsidiary of Qiagen NV, previously known as Ipsogen, leader in developing MDx-IVDs for blood-based cancers.

      
Dr. Jérôme Galon
Co-founder of HalioDx
HalioDx has a unique Immuno-Oncology (I-O) technology. HalioDx licenced a comprehensive patent portfolio from Dr. Jérôme Galon & colleagues (INSERM UMRS1138), covering clinical use of I-O biomarkers, ImmunoscoreTM concept (IHC) & gene expression signatures (MDx), Assays & biomarkers correlated to prognosis and/or response to cancer therapeutics, with patents granted in US, EU and Japan.

HalioDx has State of the art R&D, manufacturing facilities and expertise, with IVD compliant Quality System / ISO 13 485/ GMP, Fully qualified and trained staff (75 FTEs), and 1800 m2 of compliant R&D & manufacturing facilities.

Companies and institutions seeking to find out more about ImmunoscoreTM and IVD solutions, MDx and compagnion diagnostics CDx can directly contact HalioDx through:
corinne.danan@haliodx.com
aurelie.ferrier@haliodx.com


The Immunoscore

Since the original publication (Galon et al. Science 2006), the Immunoscore has grown and received interest from academic institutions, hospitals, consulting companies and other pharmaceutical companies, immunologists, oncologists, pathologists, researchers, clinicians and patients.

At present, the Immunoscore is being validated in cancers at multiple stages by more than 20 institutions worldwide. Many pharmaceutical and biotech companies expressed interest in stratifying patients using the Immunoscore.

Biopharmaceutical companies with a focus on oncology and strong interest in the field of clinical development of adjuvant therapy and immunotherapy are welcome to contact us to find out more about co-development partnership.

We are seeking for randomized clinical trial of cancer patients (any cancer type) undergoing adjuvant therapy (chemotherapy, immunotherapy, biotherapy, cell therapy)

Companies and institutions seeking to find out more about partnering opportunities can directly contact us through:
jerome.galon@crc.jussieu.fr

Companies and institutions seeking to find out more about collaborative research agreement (CRA), confidential disclosure agreement (CDA), and material transfert agreement (MTA) can directly contact INSERM-Transfert office through:
celine.smadja-belhassen@inserm-transfert.fr
augustin.godard@inserm-transfert.fr

Companies and institutions seeking to find out more about patents related to the Immunoscore can directly contact INSERM-Transfert office through:
Matthieu.collin@inserm-transfert.fr
Nicolas.crouvezier@inserm-transfert.fr